Transfer of Distribution Operation of MINIRIN MELT® and DESMOPRESSIN Formulations

Ferring Pharmaceuticals Co., Ltd.
Kissei Pharmaceutical Co., Ltd.

Ferring Pharmaceuticals Co., Ltd. (headquarter: Minato, Tokyo; CEO and Representative Director: Mark Noggle; "Ferring") and Kissei Pharmaceutical Co., Ltd. (head office: Matsumoto, Nagano; Chairman and CEO: Mutsuo Kanzawa; "Kissei") announced that Ferring has decided to transfer the distribution operation of MINIRIN MELT^® and DESMOPRESSIN formulations to Kissei in Japan (refer table below). The active ingredient of the aforesaid drugs is desmopressin acetate hydrate, which was developed by Ferring.

Brand Name	Indication
MINIRIN MELT^® OD Tablets 25μg and 50μg	Nocturia due to nocturnal polyuria in males
MINIRIN MELT^® OD Tablets 60μg, 120μg, and 240μg	Nocturnal enuresis resulted from decrease of urine osmolality or urine specific gravity^, central diabetes insipidus 120μg and 240μg only
DESMOPRESSIN Intranasal 0.01% Kyowa	Central diabetes insipidus
DESMOPRESSIN Spray 2.5 Kyowa	Central diabetes insipidus
DESMOPRESSIN Spray 10 Kyowa	Below-indicated disorder resulted from decrease of urine osmolality or urine specific gravity:　Nocturnal enuresis
DESMOPRESSIN injection 4 Kyowa	Hemostatic management of spontaneous or traumatic hemorrhage and bleeding during tooth extraction or operation in the patients with following diseases: 　Mild/moderate hemophilia A (with 2% or higher factor VIII coagulative activity) 　Type I/Type IIA von Willebrand disease

In June 2019, Ferring and Kissei entered into a co-promotion agreement for MINIRIN MELT^® OD Tablets 25μg and OD Tablets 50μg, wherein Ferring became the first company in Japan to obtain marketing authorization approval for the indication of nocturia resulting from nocturnal polyuria in males. Both companies have been collaboratively providing medical information to medical institutions.

As a result of this decision, Kissei will handle the marketing and distribution of MINIRIN MELT^® OD Tablets 25μg and OD Tablets 50μg from April 1, 2020, and of the other products from April 27, 2020. Ferring and Kissei will collaboratively promote these drugs to medical institutions.

Ferring and Kissei will contribute to improve the QOL of patients through alliances in the urology field as one of their respective strategic areas.

《Reference》

About Ferring Pharmaceuticals Co.,Ltd

The Ferring Group, founded in 1950, is a research-driven, specialty biopharmaceutical company headquartered in Switzerland. It is the worldwide leader in peptide-based and hormone-based medicines and is committed to the research, development, and marketing of innovative products in areas such as reproduction, women's health, urology, gastroenterology, endocrinology, and orthopedics. It has operating subsidiaries in nearly 60 countries and markets its products in 110 countries. Ferring Pharmaceuticals Co., Ltd., established in 2001, is its 100% subsidiary. For more details of Ferring Pharmaceuticals, please visit https://www.ferring.co.jp/

About Kissei Pharmaceutical Co., Ltd

Kissei is a Japanese pharmaceutical company based on the management philosophy "contributing to society through high-quality, innovative pharmaceutical products" and "serving society through our employees." As a strong R&D-oriented corporation, it concentrates on providing innovative pharmaceuticals to patients worldwide. Kissei is engaged in bringing new drugs into the world through drug discovery and licensing activities in the field of urology, nephrology/dialysis, and rare diseases, which are its focus fields.